Company intelligence / Profile preview
Phathom Pharmaceuticals
- Ownership
- Public · PHAT
- Employees
- ~427
- Development stage
- Phase 3
Overview
Phathom Pharmaceuticals has successfully developed and commercialized vonoprazan-based therapies for acid-related gastrointestinal diseases. Their lead product, Voquezna (vonoprazan), has received FDA approval for both erosive and non-errosive forms of GERD. Clinical trials have demonstrated that vonoprazan provides faster and more sustained relief of episodic heartburn compared to placebo. The company also markets combination regimens targeting Helicobacter pylori infection. Additional pipeline efforts include studies in eosinophilic esophagitis.
- Therapeutic areas
- GastroenterologyInfectious Diseases
- Modalities
- Small molecules (specifically potassium-competitive acid blockers, P-CABs)
- Industry
- Biotech
Drug pipeline
2 assets1 more asset in the full pipeline.
Financials
- Market cap
- $413M
- Total revenue
- $175.1M
- Enterprise value
- $396.4M
Beyond the preview
Go deeper on Phathom Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Phathom Pharmaceuticals.